Full Coverage

09:33Losses narrow at Elan as Tysabri sales rise

                   
pharmiweb.co.uk
28-Aug-2008
        
Story Timeline:  96 days

Irish pharmaceutical firm Elan has narrowed it first half loss on the back of a strong rise in sales for its multiple sclerosis drug Tysabri. Net loss for the first six months stood at $159.4 million compared to $282.6 million for the same period last year. The company posted an 18 per cent rise in revenue to $352.1 million in the first six months. Tysabri recorded in-market sales of $359.7 million, an increase... [read full story]                    

Add Comment
Latest article on this story:

FDA Advises Healthcare Providers on Tysabri Risk

 pharmiweb.co.uk 29-Aug-2008
First article on this story:

Losses narrow at Elan as Tysabri sales rise

 pharmiweb.co.uk 28-Aug-2008
Selected publications with coverage of this story:
pharmiweb.co.uk
RELATED
Found 3 documents:

FDA Advises Healthcare Providers on Tysabri Risk

pharmiweb.co.uk
29-Aug-2008
        

The FDA has issued a MedWatch informing healthcare professionals of two cases of progressive multifocal leukoencephalopathy (PML) in European patients receiving Biogen Idec and Elan’s multiple sclerosis (MS) treatment...

                   

Rise in MS drug sales helps cut Elan losses in first half

pharmiweb.co.uk
29-Aug-2008
        

Friday, 29th August, 2008 A THREEFOLD increase in sales of multiple sclerosis drug Tysabri helped Elan reduce losses significantly in the first half of the year. Overall, the Irish drug developer reported an 18 per cent...

                   

Losses narrow at Elan as Tysabri sales rise

pharmiweb.co.uk
28-Aug-2008
        

Thursday, 28th August, 2008 Irish pharmaceutical firm Elan has narrowed it first half loss on the back of a strong rise in sales for its multiple sclerosis drug Tysabri. Net loss for the first six months stood at $159.4...

Related categories